Related Experiment Video

Updated: Mar 24, 2026

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

6.1K

[Carotid barostimulation in the treatment of resistant hypertension]

Patrick Rossignol1

  • 1Inserm U1116, centre d'investigations cliniques-plurithématique 14-33, 4, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France; Institut lorrain du cœur et des vaisseaux Louis-Mathieu, CHRU de Nancy, 4, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France; Université de Lorraine, 34, cours Léopold, 54000 Nancy, France; Association Lorraine de traitement de l'insuffisance rénale (Altir), 4, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France; F-CRIN INI-CRCT (Cardiovascular and renal clinical trialists), 4, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.

Nephrologie & Therapeutique
|March 15, 2016
PubMed

Insights

Carotid barostimulation using CVRx devices may help treat resistant hypertension by electronically activating baroreceptors. This approach signals the brain to manage blood pressure and reduce organ damage associated with hypertension.

Area of Science:

  • Cardiovascular medicine
  • Neuroscience
  • Biomedical engineering

Background:

  • The autonomic nervous system is crucial in hypertension development and related organ damage.
  • Resistant hypertension poses significant health risks.
  • Existing treatments may not be sufficient for all patients.

Purpose of the Study:

  • To review clinical trial data on carotid barostimulation for resistant hypertension.
  • To evaluate the efficacy of CVRx devices (Rheos™ and Neo™) in managing hypertension.
  • To explore baroreceptor activation as a therapeutic strategy.

Main Methods:

  • Review of available clinical trial data.
  • Analysis of studies involving CVRx carotid barostimulation devices.
  • Focus on treatment outcomes in patients with resistant hypertension.

Main Results:

  • Clinical trial data suggests carotid barostimulation is a potential treatment for resistant hypertension.
  • CVRx devices aim to modulate autonomic nervous system activity via baroreceptors.
  • Further data is needed to fully establish long-term efficacy and safety.

Conclusions:

  • Carotid barostimulation represents a promising, device-based therapeutic option for resistant hypertension.
  • Electronic baroreceptor activation may offer a novel mechanism to control blood pressure.
  • Continued research and clinical trials are essential to validate this treatment approach.

Keywords:
Barostimulation carotidienneCarotid barostimulationHypertension artérielle résistanteResistant hypertension

More Related Videos

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

29.7K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

850

Related Concept Videos

Neural Regulation of Blood Pressure01:18

Neural Regulation of Blood Pressure

The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
8.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.7K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633